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Platelet Hyperreactivity: Predictive and intrinsic properties
Paul F. Bray, M.D.
Division of Hematology and the Cardeza Foundation for Hematologic Research, Jefferson Medical
College, Philadelphia, PA 19107
Abstract
Platelet thrombi are central to the development of most vascular ischemic events. There is marked
inter-individual variation in platelet responsiveness, with some subjects displaying platelet
hyperreactivity. An increasing number of reports indicate there are laboratory measures of platelet
function that predict clinical thrombotic events. Some, but not all measures of platelet function are
reproducible. Platelet hyperreactivity can be assessed with multiple stimuli in multiple assays, and
is more likely to be present in females and in subjects with elevated fibrinogen levels.
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Introduction
Occlusive vascular diseases, such as myocardial infarction (MI), are the major causes of
mortality and morbidity in the U.S. MI and other acute coronary syndromes develop when a
platelet thrombus forms at the site of a ruptured or eroded unstable coronary atherosclerotic
plaque. Pathologic platelet thrombi also cause ischemia in the brain (stroke) and extremities
(peripheral arterial disease). There is increasing evidence that enhanced platelet reactivity can
prospectively identify subjects at risk for these conditions. Increased platelet reactivity may
also mitigate hemorrhage in inherited or acquired bleed conditions. There is a well-known
inter-individual variation in platelet reactivity, which may contribute to the risk of thrombosis
in one individual, but protection in another. On the other hand, reduced platelet function may
also contribute to hemorrhagic disorders, usually in very different clinical settings. This review
will consider inherent differences in platelet function and the clinical relevance of platelet
hyperreactivity. The first section will examine patient studies linking ex vivo platelet functional
assays to clinical events. The second section will consider those variables and subject
characteristics associated with platelet hyperreactivity.
Platelets in arterial thrombosis
The pathophysiology of arterial thrombosis is complex, with many genes dictating physiologic
and biochemical traits that modify one another to increase or decrease the risk for developing
adverse clinical outcomes. Environmental factors also impinge on the risk, as do age and
gender. Figure 1 emphasizes the central role of platelets in the pathogenesis of clinical
thrombosis in arterial disease. The position of platelets in acute coronary syndromes is well
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established and is grounded in physiologic, pathologic, and clinical studies [1-3]. Platelet
deposition onto the subendothelium is proportional to the shear rate [4], such that platelets play
a particularly important role in arterial thrombosis. Upon arterial plaque rupture, von
Willebrand factor (VWF) molecules are rapidly localized to the subendothelium and the initial
platelet contact with the wound is a tethering of platelets to this insoluble form of VWF. The
glycoprotein (GP) GPIbα subunit of the GPIb-IX-V complex [5,6] mediates this tethering to
VWF, resulting in a slower platelet velocity, which in turn permits platelet GPVI to bind to
collagen [7]. Signaling between and through GPIbα and GPVI causes platelet activation,
resulting in secretion, firm platelet adhesion through activated integrins: α2β1 binding to
exposed collagen and GPIIb-IIIa (integrin αIIbβ3) binding to VWF and fibrinogen [8]. An
expanding thrombus ensues when platelets aggregate via the intercellular bridging of
fibrinogen and VWF binding to the activated conformation of GPIIb-IIIa. Blood flow ceases
when an occlusive platelet plug forms. The importance of GPIIb-IIIa, GPIbα and α2β1 is
underscored by the moderate to severe bleeding seen in patients with inherited defects in these
genes.
Platelet assays as predictors of CHD events
Substantial evidence has accumulated linking platelet hyperreactivity with vascular thrombotic
diseases. Table 1 lists conditions in which enhanced platelet reactivity have been demonstrated.
Other than heparin-induce thrombocytopenia, the mechanisms responsible for the
hyperreactivity are generally poorly understood. Most studies in this area have included
patients with acute coronary events, and have measured ex vivo markers of platelet activation.
For example, patients admitted to the coronary care unit have increased levels of circulating
P-selectin [9]. However, cross-sectional studies cannot distinguish the cart from the horse; i.e.,
did underlying platelet hyperreactivity contribute to the thrombotic event? Or did the stress of
the acute event induce platelet activation? The plethora of cross-sectional studies will not
address these questions. Prospective studies are required to appropriately test the hypothesis
that ex vivo platelet reactivity predicts coronary heart disease (CHD) outcomes. In fact, a
modest body of literature exists supporting this hypothesis. The design of most prospective
studies is as follows: 1) high-risk patients are identified, 2) any of a variety of platelet functional
assays are performed, and 3) patients are followed for variable periods of time for a variety of
different outcomes. Table 2 lists the different platelet assays that have been utilized in these
types of clinical studies.
The vast majority of research linking platelet reactivity to CHD events has utilized three routine
clinical measures of platelet reactivity: standard lumiaggregometry with platelet rich plasma
(PRP), the PFA-100® and the mean platelet volume (MPV). As summarized in Table 3A,
spontaneous aggregation, and aggregation induced by arachidonic acid, epinephrine, ADP and
collagen have all been found to predict clinical CHD outcomes. On the other hand, most studies
have not found platelet aggregation predicts re-stenosis at angiography (Table 3B), the
exception being one of the two studies by Torres et al. [12]. Both the PFA-100® and the MPV
have been found to predict CHD outcomes (Table 3C). Of note, the study by Frossard et al.
[19] utilized an intermediate outcome of troponin T levels. The largest study to test whether a
platelet parameter predicted a CHD outcome was that of Martin et al. [23]. These investigators
identified 2,033 male MI patients, and obtained hematologic studies on 1,716 patients six
months post-event. After a follow-up of approximately 24 months 126 patients had experienced
a CHD death or recurrent MI. The average MPV was significantly higher in those patients who
experienced a recurrent ischemic event compared to those who did not (P<0.001). Only one
or two prospective studies have been performed that tested the value of the last nine measures
of platelet function listed in Table 2, and these will not be reviewed in detail. However, the
report by Eikelboom et al. is noteworthy for its sample size [26]. These investigators found
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that high levels of urinary thromboxane in patients on aspirin predicted recurrent vascular
events.
It must be emphasized that there are limitations in drawing conclusions from these prospective
studies (Table 4). The patients comprising the data summarized in Tables 3A-3C are quite
heterogeneous. Differences include acute versus chronic disease, coronary versus peripheral
vessels, different lengths of follow-up, different endpoints, etc. Most of these studies were
rather small – many with fewer than 30 CHD events. There were technical differences as well
– the timing of phlebotomy from the acute event, as well as different assays and different
agonist concentrations. This type of research also lends itself to publication bias, since a study
finding no predictive value for a give platelet assay has less impact. Finally, since most study
populations included patients with vascular ischemia, nearly all subjects were on anti-platelet
medications. Many of these agents are known to affect the results of in vitro assays. In and of
itself, this does not undermine the conclusions from these studies because patients biologically
resistant to the platelet inhibitory effects of these agents might be expected to have both worse
clinical outcomes and enhanced ex vivo measures of platelet reactivity. However, only a small
number of these studies were designed specifically to consider the effect of anti-platelet agents,
with the vast majority not considering this variable in the analysis. Having acknowledged these
limitations, it is nevertheless fair to conclude that there is a substantial body of evidence – both
cross sectional and prospective – supporting the hypothesis that ex vivo platelet reactivity
predicts CHD outcomes.
Are these platelet assays clinically useful? This is quite a separate issue, and the answer is
largely related to the failure of anti-platelet therapy and whether there are alternative
approaches to “rescue” an inadequate ex vivo response to anti-platelet therapy. For example,
if a compliant patient taking aspirin for secondary prevention of MI is found to have enhanced
epinephrine-induced platelet aggregation and an MPV in the upper quartile of the normal
distribution, will they benefit from the addition of clopidogrel? These are important and
unresolved questions that need additional clinical research.
Intrinsic platelet function variation
There is a common belief that substantial inter- and intra-individual variation exists in platelet
responsiveness. This variation persistently challenges the interpretation of clinical research
involving platelet assays. To more rigorously characterize this variation and to determine the
factors contributing to this variation, we recruited a large number of healthy subjects to donate
blood samples. The design of this study has been previously detailed [36,37] and Table 5 lists
the assays that were performed. Figure 2 illustrates the variability observed amongst the first
280 subjects studied, using collagen as the agonist in platelet lumiaggregometry. Similar
variability was observed with all other agonists (not shown). Note the striking variation in a
healthy population on the “steep” portion of the dose-response curve. At the two extremes
(very little stimulation and maximal stimulation) there is considerably less variability, as
indicated by the smaller standard deviations. From the point of view of platelet risk factors for
arterial thrombosis, the subjects with maximal aggregation at low concentrations of agonist
might be considered to have a hyperreactive platelet phenotype. It is this population that is
especially interesting. Knowing the characteristics of this group could provide valuable clinical
information and provide insights into the molecular basis of platelet reactivity.
Reproducibility of ex vivo platelet assays
Table 6 lists some of the potential sources of variation in platelet functional assays. If one
wanted to characterize the contribution of any one of the factors listed in Table 6, then the
extent of variation contributed by the other factors must either be minimal or must be known
and considered in the analyses. In practical terms, knowing the reproducibility of the platelet
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assays becomes critical. Surprisingly little information exists on the reproducibility of platelet
function. This is especially important for studies with small numbers of subjects, typical of
many clinical studies and virtually all basic research studies. Because of our interest in
identifying genes that modify platelet function, we performed a formal reproducibility study
of the assays listed in Table 5. Twenty seven subjects were studied on a weekly basis for four
weeks. Subjects were studied weekly because of concerns that 1) a longer time interval might
introduce new variables, such as age, and 2) a shorter time interval would not account for the
effects of new platelet production. For agonist concentrations selected to identify a
hyperreactive phenotype, poor reproducibility was observed for collagen and ristocetin, but
there was excellent reproducibility for epinephrine and a collagen-related-peptide (CRP)
[36]. Reproducibility analyses with submaximal concentrations ADP were inconclusive.
Fifteen of the 27 subjects had had platelet function assays 2-25 months prior to the
reproducibility study. Fourteen of these 15 showed remarkably consistent results over this time
period in response to 0.4 μM epinephrine [36]. This study demonstrated that submaximal
concentrations of epinephrine and CRP can be used to assess in vitro platelet hyperreactivity.
We recommend that such a classification be limited to subjects whose platelets demonstrate
more than 60% aggregation to epinephrine or more than 50% aggregation to CRP on at least
2 occasions.
Platelet hyperreactivity is global
Subjects with hyperreactivity to epinephrine are more likely to exhibit hyperfunction in each
major aspect of platelet activity, including adhesion (response to ristocetin), activation (surface
P-selectin expression and PAC-1 binding after stimulation) and aggregation to applied shear
stress (PFA-100 and cone-and-plate viscometer) [37]. Figure 3 shows that hyperreactivity to
epinephrine was strongly associated with hyperreactivity to submaximal concentrations of
other agonists. The consistent results using different platelet function assays show that platelet
hyperreactivity is not specific to epinephrine mediated aggregation, but generalizes to multiple
forms of platelet stimulation. This indicates underlying mechanisms involved in the early
aspects of platelet activation and that are shared by multiple pathways affecting distinct aspects
of platelet function.
Factors associated with platelet hyperreactivity
Factors associated with platelet hyperreactivity are listed in Table 7. Healthy subjects
demonstrating platelet hyperreactivity did not differ significantly from subjects without
hyperreactive platelets for age, race, body mass index, smoking status, or the presence of
hypertension. The predilection of platelet hyperreactivity for female gender has been noted in
other studies in both humans [38-40] and mice [41]. The lack of association between platelet
hyperreactivity and oral contraceptive use, menopausal status, or phase of the menstrual cycle
at the time of testing among female subjects suggests an underlying genetic basis (XX vs. XY)
for this gender difference. Feng et al also found that higher fibrinogen levels were associated
with increased aggregation to epinephrine, but other factors must also contribute [37]. It seems
likely that no single factor will induce platelet hyperreactivity in most subjects, but it remains
to be determined whether combinations of the factors listed in Table 7 increase the risk of this
platelet phenotype.
Platelet genes regulating platelet variation
The genetic contributions to coronary artery disease (CAD) and arterial thrombosis are well
established [42]. We have observed strong heritability (h2) in platelet function studies on
extended family structures in whites and African Americans [43]. There are well-known
examples of inherited gene variations affecting platelet function, the best understood being
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mutations that lead to a clinical hemorrhagic phenotype (e.g., Glanzmann thrombasthenia and
storage pool diseases).
In 1990 we reported the first genetic variation in a platelet-mediated inherited bleeding disorder
[44], and since that time many other platelet gene defects have been described that produce a
clinical hemorrhagic phenotype due to platelet hypofunction. Only in the last decade have
investigators begun to consider inherited variations that enhance platelet reactivity. In 1996
we reported the first platelet genetic variation associated with acute myocardial infarction (MI)
[45]. Since then many platelet genetic epidemiology studies have been performed, but the
results have often been inconsistent (for review, see reference [46]). These inconsistencies
should not be interpreted to mean platelet genes are not involved in the pathogenesis of these
thrombotic disorders. Since thrombosis is one of several components involved in the
pathophysiology of pathologic thrombi (such as MI), the effect of a prothrombotic variations
are “diluted” by the effects of genes affecting other components of the pathogenesis of the
clinical phenotype. Ten of 11 polymorphisms in 8 platelet genes were not associated with
platelet hyperreactivity, including functional polymorphisms in genes encoding the α2
adrenergic receptor, integrins β3 and α2, and GPIbα and GP VI [37]. However, platelet
hyperreactivity was associated with the C825T polymorphism in the gene encoding the β3
subunit of G-proteins.
Summary
Platelets play a central role in ischemic arterial occlusions and enhanced platelet reactivity is
a risk factor for clinical CHD events. The use of state-of-the-art genomic, proteomic and RNA
expression studies for gene discovery will require rigorously defined platelet phenotypes.
Fortunately, platelet hyperreactivity can be easily and reproducibly detected in healthy subjects
in the absence of anti-platelet therapy. Formal reproducibility studies are needed in patients
taking aspirin and clopidogrel. Platelet hyperreactivity appears to be a global phenomenon,
observed with multiple stimuli, suggesting mechanisms that involve the early pathways of
platelet activation. There is marked inter-individual variation in platelet reactivity, and this
variation is associated with female gender, high plasma fibrinogen and genetic variation. The
future identification of novel genetic variants associated with platelet reactivity may be useful
predictors of clinical thrombotic events, as well as modifiers of bleeding disorders or
pharmacologic effects.
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Figure 1. Schema indicating the multifactorial nature of thrombosis
The central role of platelets is emphasized.
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Figure 2. Variation in platelet reactivity
The lumiaggregation response in plateletrich plasma in response to increasing concentrations
of type I acid soluble collagen is shown. The box indicates the 25th-75th percentiles, the line
in the box indicates the median, the lines outside the box indicate the 10th and 90th percentiles,
and the dots are the outliers below the 10th percentile and above the 90th percentile. An arbitrary
group of hyperreactive outliers is circled.
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Figure 3. Association between platelet hyperreactivity to epinephrine and hyperreactivity to other
agonists
The unadjusted and adjusted Odds Ratios (probability of hyperreactivity to the specified
agonist given hyperreactivity to epinephrine/probability of hyperreactivity to the specified
agonist given no hyperreactivity to epinephrine) are shown for three different agonists. As
expected, hyperreactivity to 0.4 μM epinephrine predicts hyperreactivity to 10 μM epinephrine.
The dashed line indicates the position of an OR=1.0. Every bar represents an Odds Ratio that
is significant at the <0.001 level.
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Table 1
Conditions associated with enhanced platelet reactivity.
Coronary artery disease
Cerebrovascular disease
Peripheral artery disease
Acute coronary syndromes
Percutaneous coronary interventions
Coronary artery bypasses graft surgery
Antiphospholipid syndrome
Myeloproliferative disorders
Heparin-induced thrombocytopenia
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Table 2
Platelet measures reported to prospectively predict CHD outcomes.
Assay Reference
Platelet aggregation [10-17]
PFA-100® [18-22]
Mean Platelet Volume [12,23-25]
Urinary thromboxane [26]
Platelet count [11]
Platelet secretion [27]
Platelet-leukocyte aggregates [28]
Platelet microaggregation (PA-200®) [29,30]
Platelet fibrinogen binding [31,32]
Soluble CD40L [33]
Platelet nitric oxide responsiveness [34]
Ultegra RPFA® [35]
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Table 5
Platelet functional assays.
Assay Condition (concentration or shear rate)*
PRP aggregation†
 Epinephrine 0.1, 0.2, 0.4, 1.5, 3, 10 μM
 CRP 0.005, 0.01, 0.02, 0.05 μg/mL
 ADP 0.05, 0.5, 1, 4, 20 μM
 Collagen 2.5, 5. 10, 20, 50, 200 μg/mL
 Arachidonic acid 0.5 mg/mL
 Ristocetin 0.1, 0.5, 0.75, 1 mg/mL
 Spontaneous
Whole Blood flow cytometry
 P-selectin expression 0, 1, 10 μM ADP
 PAC-1 binding 0, 1, 10 μM ADP
Shear assays†
 PFA-100 (ADP)
 PFA-100 (epinephrine)
 SIPE (cone and plate viscometer) 0, 500, 1000, 2000, 5000, 10000 sec−1
 SIPA (cone and plate viscometer) 0, 500, 1000, 2000, 5000, 10000 sec−1
Receptor density
 αIIbβ3 (CD41) resting
 GPIbα (CD42b) resting
 α2β1 (CD49) resting
 FcγRIIA (CD32) resting
Clot retraction†
*
Blank means only a single condition was used.
†
Assays also performed in PPACK anticoagulant
CRP, collagen-related peptide; SIPE, shear-induced P-selectin expression; SIPA, shear-induced platelet aggregation
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Table 6
Sources of variation in platelet functional assays
Genetic/intrinsic Environmental Technical
Genes Cigarette smoking Instruments
Alcohol Different lots of reagents
Sex hormones Phlebotomy techniques
Heparin Time of day
Plasma Changes in personnel
Unknown Processing (e.g., time, temp., transportation)
Unknown
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Table 7
Characteristics of subjects with hyperreactive platelets
• Female (p=0.016)
• Higher fibrinogen levels (p=0.009)
• Higher MPV (p<0.001)
• Hyperreactive to other agonists
• Increased platelet secretion
• Increased reactivity to shear
• Increased levels of integrin αIIbβ3 (GP IIb-IIIa)
• 825 T allele of the GNB3 exon 10 polymorphism
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